These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 17973261

  • 1. Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics.
    Vandesompele J, Michels E, De Preter K, Menten B, Schramm A, Eggert A, Ambros PF, Combaret V, Francotte N, Antonacci F, De Paepe A, Laureys G, Speleman F, Van Roy N.
    Int J Cancer; 2008 Mar 01; 122(5):1177-82. PubMed ID: 17973261
    [Abstract] [Full Text] [Related]

  • 2. Regions syntenic to human 17q are gained in mouse and rat neuroblastoma.
    Łastowska M, Chung YJ, Cheng Ching N, Haber M, Norris MD, Kees UR, Pearson AD, Jackson MS.
    Genes Chromosomes Cancer; 2004 Jun 01; 40(2):158-63. PubMed ID: 15101050
    [Abstract] [Full Text] [Related]

  • 3. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
    Spitz R, Hero B, Ernestus K, Berthold F.
    Clin Cancer Res; 2003 Oct 15; 9(13):4835-40. PubMed ID: 14581355
    [Abstract] [Full Text] [Related]

  • 4. PPM1D is a potential target for 17q gain in neuroblastoma.
    Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, Inazawa J.
    Cancer Res; 2003 Apr 15; 63(8):1876-83. PubMed ID: 12702577
    [Abstract] [Full Text] [Related]

  • 5. Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes.
    Van Roy N, Laureys G, Van Gele M, Opdenakker G, Miura R, van der Drift P, Chan A, Versteeg R, Speleman F.
    Eur J Cancer; 1997 Oct 15; 33(12):1974-8. PubMed ID: 9516836
    [Abstract] [Full Text] [Related]

  • 6. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors.
    Łastowska M, Cotterill S, Bown N, Cullinane C, Variend S, Lunec J, Strachan T, Pearson AD, Jackson MS.
    Genes Chromosomes Cancer; 2002 Aug 15; 34(4):428-36. PubMed ID: 12112532
    [Abstract] [Full Text] [Related]

  • 7. Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma.
    Lastowska M, Van Roy N, Bown N, Speleman F, Roberts P, Lunec J, Strachan T, Pearson AD, Jackson MS.
    Med Pediatr Oncol; 2001 Jan 15; 36(1):20-3. PubMed ID: 11464884
    [Abstract] [Full Text] [Related]

  • 8. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24.
    Abel F, Ejeskär K, Kogner P, Martinsson T.
    Br J Cancer; 1999 Dec 15; 81(8):1402-9. PubMed ID: 10604740
    [Abstract] [Full Text] [Related]

  • 9. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Bown N, Lastowska M, Cotterill S, O'Neill S, Ellershaw C, Roberts P, Lewis I, Pearson AD, U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Med Pediatr Oncol; 2001 Jan 15; 36(1):14-9. PubMed ID: 11464868
    [Abstract] [Full Text] [Related]

  • 10. Localization of the 17q breakpoint of a constitutional 1;17 translocation in a patient with neuroblastoma within a 25-kb segment located between the ACCN1 and TLK2 genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patients.
    Van Roy N, Vandesompele J, Berx G, Staes K, Van Gele M, De Smet E, De Paepe A, Laureys G, van der Drift P, Versteeg R, Van Roy F, Speleman F.
    Genes Chromosomes Cancer; 2002 Oct 15; 35(2):113-20. PubMed ID: 12203774
    [Abstract] [Full Text] [Related]

  • 11. Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain.
    Schleiermacher G, Bourdeaut F, Combaret V, Picrron G, Raynal V, Aurias A, Ribeiro A, Janoueix-Lerosey I, Delattre O.
    Oncogene; 2005 May 05; 24(20):3377-84. PubMed ID: 15735707
    [Abstract] [Full Text] [Related]

  • 12. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
    Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F, Nicholson J, Bernheim A, Betts DR, Vandesompele J, Van Roy N.
    N Engl J Med; 1999 Jun 24; 340(25):1954-61. PubMed ID: 10379019
    [Abstract] [Full Text] [Related]

  • 13. Variety and complexity of chromosome 17 translocations in neuroblastoma.
    Schleiermacher G, Raynal V, Janoueix-Lerosey I, Combaret V, Aurias A, Delattre O.
    Genes Chromosomes Cancer; 2004 Feb 24; 39(2):143-50. PubMed ID: 14695994
    [Abstract] [Full Text] [Related]

  • 14. Interphase fluorescence in situ hybridization detection of chromosome 17 and 17q region gains in neuroblastoma: are they secondary events?
    Trakhtenbrot L, Cohen N, Betts DR, Niggli FK, Amariglio N, Brok-Simoni F, Rechavi G, Meitar D.
    Cancer Genet Cytogenet; 2002 Sep 24; 137(2):95-101. PubMed ID: 12393279
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2.
    Godfried MB, Veenstra M, v Sluis P, Boon K, v Asperen R, Hermus MC, v Schaik BD, Voûte TP, Schwab M, Versteeg R, Caron HN.
    Oncogene; 2002 Mar 27; 21(13):2097-101. PubMed ID: 11960382
    [Abstract] [Full Text] [Related]

  • 17. Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA.
    Combaret V, Bréjon S, Iacono I, Schleiermacher G, Pierron G, Ribeiro A, Bergeron C, Marabelle A, Puisieux A.
    Pediatr Blood Cancer; 2011 May 27; 56(5):757-61. PubMed ID: 21370407
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.